DBV Technologies' lead asset, Viaskin Peanut, is being evaluated in two Phase 3 trials targeting peanut allergies. See why DBVT stock is a Hold.
Awarded for leading performance in customer satisfaction & care of belongingsLos Angeles, CA, Dec. 10, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback